CAPTRUST Financial Advisors
FATE icon

CAPTRUST Financial Advisors’s Fate Therapeutics FATE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2K Buy
41,880
+16,346
+64% +$19.9K ﹤0.01% 2896
2025
Q4 		$25.1K Buy
25,534
+6,045
+31% +$7.26K ﹤0.01% 2708
2025
Q3 		$24.6K Sell
19,489
-115
-0.6% -$124 ﹤0.01% 2596
2025
Q2 		$22K Buy
19,604
+3,175
+19% +$3.69K ﹤0.01% 2468
2025
Q1 		$13K Buy
+16,429
New +$20.1K ﹤0.01% 2331
2022
Q3 		– Sell
-474
Closed -$12K – 2712
2022
Q2 		$12K Buy
474
+465
+5,167% +$12.8K ﹤0.01% 3648
2022
Q1 		$0 Sell
9
-41
-82% -$1.59K ﹤0.01% 4973
2021
Q4 		$3K Buy
50
+25
+100% +$1.42K ﹤0.01% 4269
2021
Q3 		$1K Sell
25
-38
-60% -$2.98K ﹤0.01% 4420
2021
Q2 		$5K Sell
63
-12
-16% -$967 ﹤0.01% 3855
2021
Q1 		$6K Buy
+75
New +$7.19K ﹤0.01% 3648

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAPTRUST Financial Advisors's FATE Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Fate Therapeutics (FATE) stake by 64% in Q1 2026, buying an estimated $19.9K and bringing the position to 41,880 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

CAPTRUST Financial Advisors first reported a position in FATE in Q1 2021 and has held it in 11 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • CAPTRUST Financial Advisors held 41,880 shares of Fate Therapeutics worth $50.2K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 16,346 Fate Therapeutics shares in Q1 2026, an estimated $19.9K.
  • Fate Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2896 holding.
  • CAPTRUST Financial Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.